Your browser is unsupported
and may have security vulnerabilities!
Upgrade to a newer browser
to experience this site in all
Skip to main content
Aims & Objectives
Short acting beta agonist (SABA) inhalers do not possess any anti-inflammatory properties, yet they are the most widely prescribed inhaler treatment for asthma in the UK. SENTINEL Plus is a programme designed to improve outcomes for asthma patients through identifying and addressing SABA over-reliance.
This website is part of the SENTINEL Plus quality improvement package which has been funded by AstraZeneca and co-developed with Hull York Medical School and Hull University Teaching Hospitals NHS Trust.
This website is intended for UK Healthcare Professionals.
GB-32725 - Date of Preparation, November 2021. Copyright © University of Hull 2021